Centene Corporation (CNC) $35.11
Centene Corporation (CNC) finds itself at a critical juncture, having shed nearly half its value from its 52-week high, yet recent insider activity hints at a potential turning point.
52-wk High $66.03
📌 Investment Snapshot
- 💰 Centene trades at $35.11, with a $17.3B market cap, but lacks a P/E due to negative EPS.
- 📈 Latest quarter revenue hit $49.73B, yet EPS remained deeply negative at $-2.24.
- 🔑 Recent insider buying by directors signals potential confidence despite the stock’s significant decline.
- 🎯 Analysts maintain a ‘Hold’ consensus with a $43.18 target, implying 23% upside.
The stock has experienced significant downside pressure recently, pushing it well below its 52-week high. While insider buying signals confidence and analysts see substantial upside, the price currently trades below key moving averages (SMA50, SMA200) and the anchored VWAP, indicating short-term resistance. Despite a strong Technical Confluence Score of 80/100, driven by positive volume profile, liquidity sweeps, ADX momentum, and FVG support, the RSI at 52.9 confirms it’s not yet oversold, suggesting further consolidation or a dip might occur before a high-conviction entry emerges.
| 📍 Entry Zone | $32.88 or below | 🛑 Stop-Loss | $31.50 |
| 📋 Adjust If | CNC reclaims the $36.93 SMA200 with at least 1.5x average volume. | ||
The Investment Case — Why Now?
Centene has endured a brutal period, with its stock price plummeting over 46% from its 52-week high and a staggering 21.3% in the last month alone. This sharp decline has, however, coincided with notable insider buying activity from multiple directors in late March, a move that often precedes a reversal, signaling conviction from those closest to the company.
The primary concern remains Centene’s persistent negative EPS, with the latest reported at $-2.24 per share. While revenue growth appears stable, the inability to translate top-line expansion into bottom-line profitability poses a significant challenge, raising questions about the company’s operational efficiency and cost management strategies.
🤔 Given the recent insider buying amidst a significant price decline, are these directors signaling a true bottom, or simply averaging down into a volatile situation?
🏢 Company Overview
| Detail | Value |
|---|---|
| Company | Centene Corporation |
| Ticker / Exchange | CNC / NYSE |
| Sector / Industry | Healthcare / Healthcare Plans |
| CEO | Sarah M. London |
| Founded / HQ | 1984 / St. Louis, Missouri |
📈 Price Action & Technicals
Golden Cross
Inside VA
Two recent buy-side sweeps at $33.85 and $31.77 signal institutional accumulation below current levels.
CNC currently trades below its 50-day ($39.53) and 200-day ($36.93) Simple Moving Averages, confirming a bearish short-to-medium term trend. These levels now act as significant resistance points, challenging any upward momentum. A decisive break above these averages would be a critical bullish signal.
The RSI at 52.9 indicates a neutral stance, neither oversold nor overbought, suggesting the stock lacks immediate directional conviction. However, the MACD has just registered a golden cross, with the MACD line moving above its signal line, hinting at a potential short-term bullish shift, though both lines remain in negative territory. The strong ADX reading of 49.5, coupled with +DI (26.1) exceeding -DI (22.2), confirms a robust underlying trend with increasing bullish momentum, despite the recent price declines.
Price action remains within the Volume Area, with the Point of Control (POC) at $29.15 providing a strong psychological support level. The current price of $35.11 sits just below the Anchored VWAP from August 2025 at $35.45, suggesting this level acts as immediate resistance. A reclaim of the VWAP would signal renewed buyer interest.
Volume today is running well below average at 62% of the 20-day average, indicating a lack of strong conviction behind the current price move. The Bollinger Bands show the price near the middle band, with open bearish FVG zones at $34.78-$35.51 and $36.67-$42.05 acting as price magnets or resistance. Conversely, a bullish FVG at $32.88-$33.79 could offer support on any dip, reinforced by recent buy-side liquidity sweeps below current levels.
🤔 Despite the strong ADX indicating bullish momentum, CNC remains below its key moving averages. What specific price action would definitively confirm a reversal and invalidate the current downtrend?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| CNC | Centene Corporation | N/A |
| UNH | UnitedHealth Group Inc. | 19.2x |
| ELV | Elevance Health, Inc. | 16.5x |
| CI | Cigna Group | 11.8x |
| HUM | Humana Inc. | 17.1x |
| S&P 500 | Index Average | 21.0x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $49.73B | $-2.24 | |
| Q3 2025 | $49.69B | $-13.50 | |
| Q2 2025 | $48.74B | $-0.51 | |
| Q1 2025 | $46.62B | $2.63 |
Centene reported a Free Cash Flow of $0.2B in the latest quarter, indicating some operational cash generation despite the negative EPS. The company did not engage in any share buybacks during this period, suggesting a focus on preserving cash or investing in core operations.
🚀 Growth Drivers — What Moves the Stock
- Government Healthcare Expansion 🟡 Priced In — Centene’s strong foothold in Medicaid, Medicare, and ACA marketplace plans positions it to benefit from ongoing government healthcare program expansions and enrollment growth. This provides a stable and growing revenue base.
- Operational Efficiency & Cost Management 🟢 Upside Surprise — Despite recent profitability challenges, Centene’s management is actively pursuing initiatives to optimize medical costs and streamline operations. Successful execution of these strategies could significantly improve margins and return the company to positive EPS.
- Strategic Market Expansion 🟡 Priced In — The company continues to expand its geographic footprint and service offerings, targeting underserved markets and integrating new capabilities. This organic and inorganic growth strategy aims to capture additional market share and diversify revenue streams.
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 56,978 |
| Blackrock Inc. | 44,396 |
| AQR Capital Management, LLC | 31,798 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| COUGHLIN CHRISTOPHER J | Director | Mar 31, 2026 | Purchase | 1,140 |
| EPPINGER FREDERICK H | Director | Mar 31, 2026 | Purchase | 1,690 |
| SAMUELS THEODORE R II | Director | Mar 31, 2026 | Purchase | 943 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 2.0 |
⚠ Key Risk Factors
~$5B+ revenue at risk
~1-2% margin erosion
Continued EPS losses
~50bps cost increase
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $70.0 | $43.18 | $32.0 | 17 | Hold |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| JP Morgan | Neutral | Mar 2026 | Maintains | |
| Mizuho | Neutral | Mar 2026 | Maintains | |
| Morgan Stanley | Equal-Weight | Mar 2026 | Maintains | |
| Barclays | Overweight | Jan 2026 | Upgrades |
Analysts generally maintain a cautious stance, with a ‘Hold’ consensus, yet their average price target of $43.18 suggests substantial upside potential if the company can execute on its turnaround strategy and restore profitability.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Centene successfully executes its operational efficiency initiatives, leading to a significant improvement in medical loss ratios and a return to consistent positive EPS.
- Favorable regulatory environment and continued expansion of government-sponsored healthcare programs drive robust enrollment growth and stable revenue streams.
📊 Base Case
Centene continues to navigate a challenging profitability landscape, with revenue growth stabilizing but EPS remaining volatile. The company makes incremental progress on cost management, but external pressures limit significant margin expansion. The stock trades in line with its current analyst consensus.
🐻 Bear Case
- Persistent medical cost inflation and unforeseen regulatory headwinds further erode margins, leading to sustained negative EPS and a failure to meet turnaround targets.
- Increased competition in key markets results in market share losses, hindering revenue growth and intensifying pressure on profitability.
🎯 Investor Action Plan — By Profile
Stay on the sidelines until CNC reclaims the $36.93 SMA200 with conviction, or dips into the $32.88-$33.79 bullish FVG zone. A stop-loss at $31.50 would manage downside risk for a short-term bounce.
Monitor for a clear reversal signal, ideally a break above $39.53 (SMA50) on strong volume, confirming a shift in the intermediate trend. Consider scaling into a position if the stock consolidates above the $32.88 support, targeting a long-term turnaround.
While the long-term thesis for government healthcare remains compelling, the current profitability issues warrant caution. Wait for tangible signs of EPS improvement and a sustained uptrend before committing significant capital, focusing on the company’s ability to execute its turnaround plan.
❓ Investor FAQ — People Also Ask
Q: Why is Centene’s EPS so negative despite strong revenue?
Centene has reported significant losses, including a $-13.53 EPS TTM, largely due to higher medical costs and one-time charges. While revenue growth remains robust, profitability has been severely impacted by these operational challenges, indicating a struggle to manage expenses relative to premium income.
Q: Do recent insider purchases indicate a bottom for CNC?
Several directors recently purchased shares, which often signals confidence from within the company. However, these purchases occurred amidst a steep decline, and the stock remains below key resistance levels. It suggests conviction in the long-term value but doesn’t guarantee an immediate bottom or reversal.
Q: What are the key technical levels to watch for CNC?
Investors should watch for a decisive break above the SMA200 at $36.93 and SMA50 at $39.53, which currently act as strong resistance. On the downside, the bullish FVG between $32.88 and $33.79, along with the Volume Profile POC at $29.15, represent critical potential support zones.
📊 Want to check the current price action yourself?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investing in stocks involves risks, including the potential loss of principal. Always conduct your own due diligence and consult with a qualified financial advisor before making any investment decisions. The views expressed are those of the analyst and do not necessarily reflect the views of Goldman Sachs or its affiliates.
All active positions and their real-time performance are tracked on our Investment Log.
#CNC #CenteneCorporation #HealthcareStocks #StockAnalysis #Veqtio #USStocks #MarketTrends #Investing